This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA Prescribing Information for Great Britain click here. BESPONSA Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).1
BESPONSA is recommended by NICE as an option for treating relapsed or refractory CD22-postive B-cell precursor ALL in adults2. People with relapsed or refractory Philadelphia chromosome positive disease should have had at least 1 tyrosine kinase inhibitor2.
Log in/Register to PfizerPro to access further information on BESPONSA including:
Resources to support you
Across a series of short videos, watch Dr Anna Castleton provide an update on the current upfront approaches in Adult B-cell and Ph-Positive ALL and the management of relapse disease including the role of CAR-T therapy.
Dr. Emma Nicholson discusses the evolving treatment landscape in R/R B-cell ALL in the context of a 60-year-old patient case study as well as providing a particular focus on the targeted therapies available for use in R/R ALL.
Download materials to support you with the use of BESPONSA and managing patients with ALL.
Watch on-demand videos from KOLs exploring the ALL landscape and patient case studies.
ALL , acute lymphoblastic leukaemia; B-cell ALL, B-cell acute lymphoblastic leukaemia; CAR, chimeric antigen receptor; KOL, key opinion leader; Ph-positive ALL, philadelphia chromosome-positive acute lymphoblastic leukaemia; R/R, relapsed/refractory.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024